Physician profile
Frederick J Kogan
NPI 1831146117
$704.11
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $252 · 2021: $157.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $147.20 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.52 | 2019-2021 | |
| Gilead Sciences, INC. | $82.87 | 2019-2020 | |
| Qol Medical, LLC | $70.20 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $64.57 | 2019-2021 | |
| Exelixis INC. | $39.06 | 2019 | |
| Dynavax Technologies Corporation | $33.32 | 2020-2021 | |
| Shionogi INC | $31.41 | 2019-2020 | |
| Pfizer INC. | $30.98 | 2019 | |
| Shire North American Group INC | $17.34 | 2019 | |
| Janssen Biotech, INC. | $15.24 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.20 | 2020 | |
| Ironwood Pharmaceuticals, INC | $13.58 | 2020 | |
| Celgene Corporation | $13.08 | 2021 | |
| W. L. Gore & Associates, INC. | $12.54 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Kogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.